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The purpose of the present study was to explore the outcome, cumulative dose in tumor 
and organs at risk and toxicity after extra-cranial stereotactic re-irradiation. Twenty-seven 
patients were evaluated who had been re-irradiated with stereotactic body radiotherapy 
(SBRT) after conventional radiotherapy (CRT). The dose summation of the SBRT and CRT 
plans was done by dose point calculations accounting for fraction size by the linear-quadratic 
model. Efficacy and toxicity was scored by looking at the reduction in tumor size, pain and 
bleeding. Symptomatic response was observed in 96% of the patients. The median maxi-
mum SBRT dose to the tumor was 90 Gy3 (range: 42-420 Gy3). The median cumulative dose 
for the rectum, bowel and bladder resulted in 104 Gy3, 98 Gy3 and 113 Gy3, respectively. No 
grades 5, 4 and 3 acute and late toxicity was observed. In conclusion: re-irradiation to the 
same region using extra-cranial stereotactic radiotherapy is feasible and resulted in a 96% 
symptomatic response with low toxicity.
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Introduction
Despites the progress in local and combined systemic treatments in patients with 
cancer, metastasis or local failure can occur. Re-irradiation should be considered, 
if surgery or chemotherapy is not an option. Re-irradiation, however, is often 
limited by dose constraints to anatomical structures surrounding the tumor. The 
potential toxicity to surrounding tissues such as spinal cord, bowel, bladder and 
other organs limits the high dose needed to treat the tumor adequately. For organs 
in the abdominal and pelvic region, the spinal cord with its nerves is probably the 
most important organ. On the other hand, bowel, rectum and bladder and some-
times the kidneys are also dose limiting structures. 
Throughout the years, various studies reported the maximum doses that are 
acceptable for normal tissues. Clinical re-irradiation studies of the myelum 
showed little incidence of radiation myelopathy (1-4) and animal studies showed 
that retreatment tolerance of the myelum increases with increasing interval from 
the first radiation treatment. An assumption of a median of 50% repair of the 
myelum after 6 to 12 months is feasible (5-9). Re-irradiation studies regarding 
recurrences from rectum cancer, showed a cumulative medium dose of 85 Gy 
with a maximum cumulative dose of 119 Gy (10-13). The surrounding tissue 
like bladder and bowel were in the re-irradiation field, but unfortunately the 
cumulative doses were not reported. There were no grade 4 acute and late 
toxicities and there was a small number of grade 3 toxicity.
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So, it seems to be feasible to re-irradiate if other treatment 
options are ineffective or not possible. However, it remains 
difficult to retreat previous irradiated fields with conventional 
external beam radiation due to the high doses given to the 
organs at risk. Radiation treatment by stereotactic body radio-
therapy (SBRT) could have an advantage in some oncology 
patients compared with conventional external beam radiation 
therapy (EBRT). SBRT has the advantage of delivering many 
noncoplaner beams from a wider solid angle. This result in 
delivering high doses of radiation to the target volumes com-
bined with sub-millimetre accuracy. The expose of radiation 
dose to the surrounding healthy tissues is minimized, due to 
steep decrease in dose gradients. Extra-cranial use of SBRT 
in patients with malignancies has been evaluated in different 
regions. However there are only a few reports on the efficacy 
of SBRT re-irradiation in the abdomen and pelvis. Patients 
with recurrent spinal tumors, who received initial median 
radiation dose of 35 Gy, showed a median survival of 10.5 
months after SBRT re-irradiation. The re-irradiation dose 
given was 21.05 Gy in 3 fractions (14). SBRT re-irradiation 
doses given to 5 patients with gynaecological recurrences 
were between 15 Gy and 24 Gy, given in 3 fractions. The ini-
tial treatment in some patients was external beam radiation 
45 Gy in 25 fractions, with or without brachytherapy (15).
The available studies about SBRT re-irradiation involved 
little group of patients, without clear information about the 
maximum given dose to the organs at risk. 
Therefore, the purpose of the present study was to explore the 
outcome, cumulative dose in tumor and organs at risk, and 
toxicity after abdominal or pelvic stereotactic body radiother-
apy in 27 patients who were treated at our department. 
Methods and Materials
Patient Characteristics
Between March 2005 and July 2009, 33 patients have been 
re-irradiated in the pelvic region, by stereotactic body radio-
therapy (SBRT) using the CyberKnife (Accuray, Sunnyvale). 
The re-irradiated region had a partial or complete overlap with 
the previous irradiated region. Six patients were excluded 
from the analyses. Four of them had their first radiation treat-
ment in another hospital. The conventional localization films 
of the radiation fields of the other 2 patients were not avail-
able. For these 6 patients it was not possible to determine the 
precise cumulative dose in the points of interest. The remain-
ing 27 patients were included in the analysis.  There were 13 
females (48%) and 14 males (52%). The patient character-
istics are shown in Table I. Most of the patients had rectal 
cancer as primary tumor. Patient age at re-irradiation by ste-
reotactic radiotherapy ranged from 27-80 years (median: 59 
years). The median SBRT dose was 34 Gy (range: 8-60 Gy) 
in 1-10 fractions (Table II). To evaluate whether the outcome 
of stereotactic re-irradiation was dose dependent, the patients 
were classified in a group receiving a total recalculated dose 
of less than 60 Gy10, and another group receiving more than 
60 Gy10 or more. Seven patients were treated with curative 
intention.
Dose Summation and Organ Constraints
Different doses and fractionation schemes were used dur-
ing the treatment course. Therefore, all treatment schedules 
were recalculated to a biologically equivalent schedule 
of 2-Gy fractions. The dose was recalculated by the for-
mula: EQD2 5 D * (d 1 α/β) / (2.0 1 α/β) with D is the 
total dose of a treatment course, d is the fraction dose, and 
α/β 5 3 Gy for the organs at risk and α/β 5 10 Gy for the 
tumor. The organs at risk were delineated in the planning 
CT scan. 
The treatment planning system used for SBRT was On Target 
(version 3.4.1). All patients were treated in a vacuum cast. 
Prior to treatment, markers were placed in or near the tumor 
for position verification. The margins from GTV to PTV 
were 2 or 3 mm.  The first radiation treatment of 26 patients 
was performed by conventional external beam radiother-
apy. Twenty-three patients were planned with the CadPlan 
treatment planning system (Varian, version R.6.4.7) and 3 
patients with the XIO planning system (Elekta-CMS, version 
4.3.3.12). One patient was initially treated with SBRT. Dose 
summation poses many challenges. These challenges are not 
only related to technical issues, such as the absence of stan-
dardized output of dose matrices, but also to more fundamen-
tal issues such as the deformed patient’s anatomy between 
the 1st and 2nd treatment course. Here, dose summation was 
carried out by using a simple approximation: dose point cal-
culation. The maximum dose of the critical organ of interest 
was traced in the planning CT scan of the first radiation treat-
ment. Subsequently, the corresponding slice of the planning 
CT scan of the 2nd treatment was identified and the maximum 
dose inside the organ at that slice was added to the maximum 
dose of the 1st treatment. 
Table I
Patient characteristics.
No. of patients %
Primary tumor Rectum cancer 13 48
Cervix cancer  6 22
Ovarian cancer  2  7
Sarcoma  2  7
Other cancer  4 15
Re-irradiation region Pelvis 21 78
Intra-abdominal  6 22
Gender Female 13 48
 Male 14 52
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To keep the toxicity to a minimum, constraints for organs at 
risk were used during treatment planning of the re-irradiation 
treatment. For rectum and bowel, the cumulative maximum 
dose was 110 Gy3. A maximum volume of 10 cc bowel or 
rectum was allowed to receive a higher dose. The cumula-
tive maximum dose to the bladder was 120 Gy3, where 10 cc 
of bladder was allowed to get a higher dose. However, if the 
tumor was located inside the rectum, bowel or bladder, then 
a larger volume was allowed to receive a dose higher than 
the allowed maximum dose. For each organ, the volumes 
receiving more dose than the prescribed constraints were 
determined. The total dose given to an organ at risk with 
external beam radiation in the overlapping treatment volume 
was calculated in EQD2 (e.g.: 50 Gy in 2 Gy/fraction is 50 Gy 
EQD2). This dose was subtracted from the maximum dose 
allowed by the constraint (e.g.: 110 Gy3 for the bowel, in our 
example: 110 Gy-50 Gy3 is 60 Gy3, so 60 Gy3 is left). This 
dose in EQD2 was recalculated to a dose per fraction and the 
total dose in the SBRT plan (e.g. for a patient who will receive 
6 fractions, a total dose of 34.2 Gy3 equals 60 Gy3 EQD2). The 
OAR in the SBRT plan was contoured only in the overlapping 
area. The percentage of the organs at risk receiving this dose 
(in our example 34.2 Gy3) was looked up in the On 
Target planning system. By multiplying this percent-
age with the volume of the delineated organ at risk in 
the overlapping treatment volume, the volumes of the 
organ at risk receiving a cumulative maximum dose 
higher than the constraint was derived.
Toxicity and Efficacy
The toxicity and efficacy of the re-irradiation was scored 
for each patient, by collecting response, time of response 
and complications from patient’s hospital medical 
records. Twenty-one patients were followed by diag-
nostic scans every 3 to 6 months. In six patients there 
was no diagnostic scan, because of short survival after 
the treatment or due to progression of the disease. The 
response to the radiation in patients treated with pallia-
tive intention was scored by looking at the reduction in 
tumor size, pain and bleeding.  In the patients treated with 
curative intention, the response was scored by recurrence 
free interval. Toxicity was scored with the RTOG toxic-
ity criteria (16). Patients were followed by the radiation 
oncologist, 3 months after the radiation. Three patients 
were lost to follow up. The median follow up after SBRT 
re-irradiation was 15 months (range: 2-52 months). 
Results
Efficacy and Survival
Ninety-six percent of the patients responded to the ste-
reotactic re-irradiation. Reduction in tumor size and pain 
reduction were the main effects after stereotactic re-irradiation, 
seen in respectively 100% and 95% of the patients. In 75% of 
the patients there was a reduction in bleeding. The 1-year and 
2-year local control rate for the whole group was 64% and 53%, 
respectively. Looking at the two different groups with patients 
classified by the dose given by SBRT, the 1-year and 2-year 
local control rate for the group of patients receiving 60 Gy or 
less was 53% and 40%, respectively. Whereas the 1-year and 
2-year local control rate for the group of patients who received 
more than 60 Gy was 100% (Figure 1). This difference was sig-
nificant (p 5 0.04). The median overall survival for all patients 
was 14 months (range: 2-56 months). The 1-year and 2-years 
overall survival was 52% and 37%, respectively. The 1-year 
overall survival of patients treated with 60 Gy or less was 45%. 
Whereas the 1-year overall survival of patients treated with 
doses higher than 60 Gy was 71%. The difference in overall 
survival was not significant (p 5 0.2).
Radiation Dose
The median maximum SBRT re-irradiation dose, converted 
to an equivalent dose in 2-Gy fractions, was 90 Gy3 (range: 
Table II
Cyberknife schedules.
Second radiation First radiation
Patient Fraction Fraction dose (Gy)
EQD2 dose 
(Gy10)
Prescripted  
isodose line (%)
EQD2 dose 
(Gy10)
1 3 20 150 80 50
2 3 15  94 85 46
3 6  8  72 80 48
4 6  8  72 80 50
5 6  7  60 80 46
6 6  7  60 80 46
7 6  7  60 70 46
8 6  6  48 80 66
9 6  6  48 75 46
10 6  6  48 80 72
11 6  6  48 65 39
12 4  8  48 80 46
13 6  6  48 80 50
14 6  6  48 75 66
15 5  6  40 80 83
16 4  7  40 75 70
17 5  6  40 79 31
18 3  8  36 80 71
19 3  6  24 80 76
20 3  6  24 80 46
21 2  8  24 80 80
22 2  8  24 80 42
23 3  6  24 80 46
24 2  8  24 80 87
25 3  6  24 85 48
26 3  6  24 80 48
27 2  8  24 70 78
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42-420 Gy3). The median PTV size was 154 cc (range: 
6.7-1114.5 cc). The median maximum cumulative dose 
(1st 1 2nd treatment) was 152 Gy3 (range: 93-468 Gy3). This 
resulted for the rectum and bowel in a median cumulative 
dose of 104 and 98 Gy3, respectively (Table III). The rec-
tum and bowel of 7 patients received more than 110 Gy. The 
median volume of normal tissue that received a dose above 
110 Gy3 was 11.6 cc (range: 0.7-99 cc). The constraint that 
no more than 10 cc should receive more than 110 Gy3 was 
exceeded in 3 of 7 patients. For these 3 patients, the volume of 
bowel or rectum receiving more than 110 Gy was 36 cc, 38 cc 
and 99 cc. The 3 patients had a local recurrence in the pelvis, 
close to or growing in the bowel/rectum. The median cumu-
lative dose for bladder was 113 Gy3. Five patients received a 
dose above 120 Gy3 on the bladder. The median volume of 
the bladder tissue receiving a dose above 120 Gy3 was 1.7 cc 
(range: 0.0-17 cc).
Toxicity
There were no patients with grade 5, 4 or 3 acute toxicity after 
re-irradiation by stereotactic radiotherapy (Table IV). Grade 2 
acute pain was seen in 7% of the patients. Seven percent of 
the patients had grade 2 acute skin toxicity. Grade 2 acute 
nausea was seen in 11% of the patients. Grade 2 vomiting and 
diarrhea was seen in 4% of the patients. Grade 1 acute pain 
was seen in 15% of the patients. Seven percent of the patients 
had grade 1 acute skin toxicity. Grade 1 dysphagia, nausea 
and diarrhea was seen in 4% of the patients. 
None of the patients experienced clinically grade 5, 4 or 3 
late toxicity. Grade 2 pain, skin, nerve complaints and dysu-
ria was seen in 4% of the patients. Seven patients experienced 
grade 2 limb dysfunction. These patients had moderate stiff-
ness and pain of their joint due to the radiation, which was 
controlled by pain medication. Grade 1 nerve complaints 
were seen in 15% of the patients. They experienced mild 
numbness in a limb. Grade 1 dysuria was seen in 11% of the 
patients. 
Four out of seven patients who received a total re-irradiation 
dose above 110 Gy3 on the bowel and rectum experienced 
low grade toxicities: one patient experienced grade 1 acute 
pain toxicity. This patient also experienced grade 2 late nerve 
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Figure 1: Local control of patients treated with high (-) (.60 Gy) and low (--) (#60 Gy).
Table III
Cumulative dose (EQD 2 / α/β 5 3 Gy) given to the organs at risk after 
stereotactic re-irradiation. 
Median Mean Min Max No. of patients
Bowel  98  97 56 144 18
Rectum 104 103 65 129 10
Bladder 113 116 79 235 13
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complaints. The other three patients experienced late grade 
1 and 2 dysuria and acute grade 1 nausea and diarrhea.
Discussion
In our study, 96% of the patients responded on the stereotactic 
re-irradiation. Tumor reduction and pain reduction were the 
main effect, in 100% and 95% of the patients, respectively. 
This effect of re-irradiation with SBRT corresponds with the 
results of previous studies on re-irradiation with conventional 
radiotherapy. Lingareddy et al. (13) reported high symp-
tomatic response in patients with recurrent rectal cancer. 
The bleeding was palliated in all patients. Pain and reduc-
tion of tumor mass was seen in respectively 65% and 24% 
of the patients (17). The same effect was seen in the long 
term results. The palliative effect of re-irradiation was 100% 
for bleeding. Pain and reduction of tumor mass was seen in 
respectively 55% and 25% of the patients (18). Juffermans 
et al. (10) evaluated that good or complete palliative effect 
was achieved in 72% of the patients with recurrent colorectal 
carcinoma, also after conventional radiotherapy (19). To 
evaluate if the dose of the SBRT re-irradiation has impact on 
the outcome, the patients were divided in 2 groups. One group 
of patients was treated with a high stereotactic re-irradiation 
dose of more than 60 Gy3. The second group of patients was 
treated with a low stereotactic re-irradiation dose 60 Gy3 
or less. The group of patients treated with high SBRT 
re-irradiation dose the 1-year and 2-year local control rate con-
trol rate was 100%. The second group of patients had a 1-year 
and 2-year local control rate of 53% and 40%, respectively. 
Although the number of patients in the both patients group 
were not equally, the local control in patients treated with 
higher stereotactic re-irradiation dose is significant better 
than in patients treated with lower stereotactic re-irradiation 
dose. The one year overall survival rate in the group treated 
with high SBRT re-irradiation dose was 71%, whereas the 
one year overall survival in the group treated with 
low SBRT re-irradiation dose was 45%. These differ-
ences in overall survival weren’t significant. Although 
there aren’t many reports on SBRT re-irradiation, the 
found local control for the patients with high stereot-
actic radiation dose corresponds with other studies 
evaluating the use of stereotactic radiotherapy for 
re-irradiation. Roh et al. (20) evaluated stereotactic 
re-irradiation in head and neck cancer patients. All 
patients had previously been treated with full-dose 
irradiation ranging between 39.6 to 134.4 Gy. The re-
irradiation dose ranged from 30 to 40 Gy delivered in 
3 to 5 fractions. The 1 and 2 year local recurrence-
free survival rates were 61% and 52%, respectively. 
The 1 and 2 years overall survival rates were 52% and 
31%, respectively. The response rate was 43%. There 
was no grade 4 acute toxicity reported. In 8% of the 
patients there was grade 4 late toxicity (20). 
In this study the median maximum SBRT re-irradiation dose 
given was 90 Gy3.The median maximum cumulative dose 
given after external beam radiation and SBRT radiation was 
154 Gy3. This resulted in a median cumulative dose given to 
the rectum and bowel of 104 Gy3 and 98 Gy3, respectively. In 
previous studies on conventional radiotherapy re-irradiation, 
the reported dose to the rectum is around 100 Gy3 (10, 17, 
18, 21). Because of the low toxicity reported and the use of 
SRT with the steep dose fall off and the small volumes, we 
used a constraint of a cumulative maximum dose of 110 Gy3 
with a maximum of 10 cc tissue for rectum and bowel. Seven 
patients received a dose above 110 Gy3 on the rectum or bowel. 
Three of these patients exceeded the maximum volume of tis-
sue, respectively 35.8 cc, 38 cc and 99 cc. In all these three 
patients the tumor was a local recurrence in the pelvis, close to 
the bowel or in the rectum. Because no other good treatment 
options existed for these patients with tumor in the organs at 
risk and with clinically a lot of pain, this was accepted by patient 
and physician. The bladder received a median cumulative dose 
of 114 Gy3. From animal studies and daily practice, it is know 
that the tissue of the bladder can handle a higher dose than the 
tissue of rectum and bowel. Therefore, the constraint for the 
bladder was set on a cumulative maximum dose of 120 Gy3 
with a maximum of 10 cc tissue. Five patients received doses 
above 120 Gy3. Two of them exceeded slightly the maximum 
volume constraint for normal tissue (15 cc and 16 cc) with a 
good coverage of the tumor, so this was accepted.
Despite the high cumulative dose given with SBRT re-
irradiation after an initial external beam radiation, the toxic-
ity was rather low. There was no grade 4 or 3 acute or late 
toxicity. Only grade 2 acute toxicity was seen. Although 89% 
of the patients had a longer follow than 6 months, the ques-
tion raises if there would have been more late toxicity if the 
survival of the whole group was longer than 2 years. On the 
Table IV
Toxicity. 
Acute toxicity (%) Late toxicity (%)
RTOG grd 1 grd 2 RTOG grd 1 grd 2
Pain 15  7 Pain  0 4
Skin  7  7 Skin  0 4
Diarrhea  4  4 Diarrhea  4 0
Proctitis  0  0 Abdominal pain  0 0
Nausea  4 11 Nausea  0 0
Vomiting  0  4 Incontinence  0 0
Dysuria  4  0 Dysuria 11 4
Dysphagia  4  0 Nerve complaints 15 4
Limb dysfunction  4 7
*RTOG: Radiation therapy oncology group.
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other hand, it corresponds with the low percentage of grade 
3 and 4 acute and late toxicity reported in other studies with 
conventional external beam radiation (10, 17, 18, 22, 23). 
Gagnon et al. (14) evaluated the effects of SBRT on pain 
and quality-of-life outcomes in patients with spinal tumors 
mainly previously treated with conventional radiotherapy to 
a median dose of 35 Gy. There were no grade 3 or 4 acute 
toxicities and 2 patients experienced grade 4 late toxicity 
after a re-irradiation dose of 21.05 Gy in 3 fractions (14). 
In our study we have shown that stereotactic re-irradiation has 
a high response with low toxicity. This could be explained by 
the capability of the stereotactic radiation device to deliver 
many non-coplanar beams from a wider solid angle, resulting 
in a rather higher degree of dose fall-off gradient outside the 
PTV. This leads to less normal tissue being included in the 
high-dose region which leads to lesser toxicity. 
However, the design of this study can be discussed, because 
of the retrospective character and the small number of 
patients. Another point of discussion could be the dose sum-
mation of both irradiation treatments, which was done by a 
point-dose addition. Non-rigid registration techniques that 
yield an anatomical coherent correspondence between tissue 
of the 1st and 2nd CT are required to accumulate dose in three 
dimensions. The development of those non-rigid registration 
techniques is in progress (24-26). However, validation is still 
challenging. To compensate for the different fraction doses 
used in this study, the physical dose was converted to a bio-
logically equivalent dose using the linear-quadratic model 
(LQ-model). Many studies used the LQ-model to convert 
relatively high fraction doses (27-30). Some studies conclude 
that this model may have limitations if the dose per fraction 
is too high, other conclude that it could be used looking at 
the survival data. Several groups have tried to design a new 
model (30, 31). All these studies do not implicate the dose 
summation in re-irradiation. Besides a validated alternative 
model has not yet been established.
In conclusion, re-irradiation to the same region using extra-
cranial stereotactic radiotherapy is feasible and resulted in a 
96% symptomatic response with low toxicity.
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